Granted, you don’t often see the words "cardiologist" and "strip club" in the same sentence, but a cardiologist in New Jersey and three other high-wealth people claim that they were victims of a scheme that involved being drugged and taken to a strip club. Once there, their companion would rack up charges on their credit cards; in the case of the cardiologist, $135,000. The New York Times is following the case.

Eight leading British physicians took the National Institute for Health and Care Excellence (NICE) to task over draft guidelines that recommend anyone with a 10 percent 10-year risk of cardiovascular disease become eligible for statin therapy. NICE fired back in an article published June 10 in The Guardian.

The cardiovascular service line may be evolving, but one trend is clear: Service lines play an increasingly important role in high-quality, efficient patient care. There is no cookie-cutter formula to success but there are guideposts, as leaders will share in an upcoming MedAxiom Cardiovascular Service Line Symposium.

The low adoption rate of an EHR-based intervention to prevent secondary stroke likely doomed its effectiveness, based on results published online June 5 in Stroke.

LUMEDX Corporation, a leading provider of cloud-based cardiovascular imaging and information systems (CVIS), and Scientific Software Solutions, Inc., (SSS), maker of PedCathcongenital catheterization (cath) reporting software, announced today that they are partnering to create an innovative solution for congenital cardiac data and image management.

This week we celebrated my father-in-law’s 90th birthday. It is a testament to the cardiac care he has received over several decades.

Many diabetic patients with chronic stable angina who are treated with ranolazine report an improvement to their quality of life. The findings, which were published June 2 in JAMA Internal Medicine, follow up on results that showed the drug reduced frequency of angina events.

Physicians and teaching hospital staff now have access to a portal that eventually will allow them to track and challenge data on financial relationships with manufacturers, as mandated under the Sunshine Act.